Jiangsu Simcere Pharmaceutical Co., Ltd. sell "XIANNUOXIN"
Basic Information
462
25
2
4.5(52)
Subcategory & Sub-subcategory
Trade Type
Sell
Product Name
XIANNUOXIN
Details
Manufacturer(s)
Specifications
- Dosage Form: Co-packaged oral film-coated tablets: simnotrelvir tablets plus ritonavir tablets
- Strength: Simnotrelvir 375 mg (as 3 x 125 mg tablets) co-packaged with ritonavir 100 mg, taken orally twice daily
- Indication: Treatment of mild-to-moderate COVID-19 in adult patients at risk of progression to severe disease
- Regulatory Approval Status: Approved by China's Center for Drug Evaluation (CDE/NMPA) as a domestically developed oral 3CL-protease inhibitor for COVID-19
Other Information
Additional Description:
XIANNUOXIN pairs simnotrelvir tablets with ritonavir tablets in a co-packaged regimen and is billed as the first China-developed oral small-molecule 3CL-protease inhibitor for COVID-19 to receive CDE approval. Selected for a key State Council joint prevention-and-control research project, it is indicated for adults with mild-to-moderate COVID-19 regardless of high-risk status.
Ratings
(0)
(0)
(0)
(0)
(0)
Comments
Filters:
Sort by:
No comments available.
Matched Products & Services
B2B matches based on trade type, category, specifications & price range
Similar Products & Services
Products & Services related to what you're viewing
People Also Viewed
Other products & services viewed by people who looked at this product
Leave your rating & comment